{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:57:22Z","timestamp":1757627842780,"version":"3.44.0"},"publisher-location":"Cham","reference-count":50,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783032029355"},{"type":"electronic","value":"9783032029362"}],"license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-02936-2_9","type":"book-chapter","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:14:23Z","timestamp":1756462463000},"page":"102-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ReDPT-CT: Designing Responsible Digital Process Twins for Clinical Trials"],"prefix":"10.1007","author":[{"given":"Luiz Ricardo Brito","family":"Ribeiro","sequence":"first","affiliation":[]},{"given":"Silvia","family":"Dallavalle","sequence":"additional","affiliation":[]},{"given":"Gerald","family":"Kremer","sequence":"additional","affiliation":[]},{"given":"Rainer","family":"Stark","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","unstructured":"Peyro\u2010Saint\u2010Paul, L., et al.: Compensating patients in trials: perspectives from an ethical committee versus sponsor. Eur. J. Clin. Invest. 53(10) (2023)","DOI":"10.1111\/eci.14044"},{"issue":"24","key":"9_CR2","doi-asserted-by":"publisher","first-page":"13386","DOI":"10.1073\/pnas.1919906117","volume":"117","author":"J Adda","year":"2020","unstructured":"Adda, J., Decker, C., Ottaviani, M.: P-hacking in clinical trials and how incentives shape the distribution of results across phases. Proc. Natl. Acad. Sci. 117(24), 13386\u201313392 (2020)","journal-title":"Proc. Natl. Acad. Sci."},{"key":"9_CR3","doi-asserted-by":"crossref","unstructured":"Miller, J., Ross, J.S., Wilenzick, M., Mello, M.M.: Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ l4217 (2019)","DOI":"10.1136\/bmj.l4217"},{"issue":"6","key":"9_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s11948-017-9966-3","volume":"24","author":"A Ozaki","year":"2018","unstructured":"Ozaki, A.: Conflict of interest and the CREATE-X trial in the New England journal of medicine. Sci. Eng. Ethics 24(6), 1809\u20131811 (2018)","journal-title":"Sci. Eng. Ethics"},{"key":"9_CR5","doi-asserted-by":"crossref","unstructured":"Eaton, M.L., Kwon, B.K., Scott, C.T.: Money and morals, pp. 297\u2013315 (2014)","DOI":"10.1007\/7854_2014_337"},{"key":"9_CR6","doi-asserted-by":"crossref","unstructured":"Coutellec, L.: Ethics and scientific integrity in biomedical research. In: Handbook of Research Ethics and Scientific Integrity, pp. 1\u201314. Springer International Publishing, Cham","DOI":"10.1007\/978-3-319-76040-7_36-1"},{"issue":"s1","key":"9_CR7","first-page":"26","volume":"6","author":"A Pascalev","year":"2022","unstructured":"Pascalev, A.: 191 ethical considerations of decentralized clinical trials. J. Clin. Transl. Sci. 6(s1), 26\u201327 (2022)","journal-title":"J. Clin. Transl. Sci."},{"key":"9_CR8","doi-asserted-by":"crossref","unstructured":"Dumas, M., La Rosa, M., Mendling, J., Reijers, H.A; Fundamentals of Business Process Management. Springer Berlin Heidelberg (2018)","DOI":"10.1007\/978-3-662-56509-4"},{"issue":"17","key":"9_CR9","doi-asserted-by":"publisher","first-page":"6827","DOI":"10.3390\/su12176827","volume":"12","author":"T Ahmad","year":"2020","unstructured":"Ahmad, T., Van Looy, A.: Business process management and digital innovations: a systematic literature review. Sustainability 12(17), 6827 (2020)","journal-title":"Sustainability"},{"key":"9_CR10","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1097\/01.MIB.0000184850.46440.ea","volume":"11","author":"WJ Tremaine","year":"2005","unstructured":"Tremaine, W.J., Carlson, M.R., Isaacs, K.L., Motil, K.J., Robuck, P.R., Wurzelmann, J.I.: Ethical issues, safety, and data integrity in clinical trials. Inflamm. Bowel Dis. 11, S17\u2013S21 (2005)","journal-title":"Inflamm. Bowel Dis."},{"key":"9_CR11","doi-asserted-by":"publisher","unstructured":"Kremer, G., Ribeiro, L.R.B., Bl\u00fcher, T., Dallavalle, S., Stark, R.: Towards a unified approach: developing a reference model for digital twins and business process management in clinical trials. In: Gdowska, K., G\u00f3mez-L\u00f3pez, M.T., Rehse, JR. (eds.) Business Process Management Workshops. BPM 2024. Lecture Notes in Business Information Processing, vol. 534. Springer, Cham (2025). https:\/\/doi.org\/10.1007\/978-3-031-78666-2_30","DOI":"10.1007\/978-3-031-78666-2_30"},{"key":"9_CR12","doi-asserted-by":"crossref","unstructured":"Damjanovic-Behrendt, V.: A digital twin-based privacy enhancement mechanism for the automotive industry. In: 2018 International Conference on Intelligent Systems (IS), pp. 272\u2013279. IEEE (2018)","DOI":"10.1109\/IS.2018.8710526"},{"issue":"13","key":"9_CR13","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3897\/jucs.114607","volume":"30","author":"M Ku\u0161telega","year":"2024","unstructured":"Ku\u0161telega, M., Mekovec, R., Shareef, A.: Privacy and security challenges of the digital twin: systematic literature review. JUCS \u2013 J. Univ. Comput. Sci. 30(13), 1782\u20131806 (2024)","journal-title":"JUCS \u2013 J. Univ. Comput. Sci."},{"key":"9_CR14","doi-asserted-by":"crossref","unstructured":"Alja\u2019afreh, M., Ahmad, O.B., Karime, A.: Enhancing privacy and security in digital twin and metaverse technologies: mathematical models, blockchain, and future directions. In: 2024 2nd International Conference on Intelligent Metaverse Technologies and Applications (iMETA), pp. 070\u2013077. IEEE (2024)","DOI":"10.1109\/iMETA62882.2024.10807913"},{"issue":"1","key":"9_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1108\/MD-07-2015-0279","volume":"54","author":"DL Parris","year":"2016","unstructured":"Parris, D.L., Dapko, J.L., Arnold, R.W., Arnold, D.: Exploring transparency: a new framework for responsible business management. Manag. Decis. 54(1), 222\u2013247 (2016)","journal-title":"Manag. Decis."},{"issue":"5","key":"9_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12599-017-0487-z","volume":"59","author":"WMP van der Aalst","year":"2017","unstructured":"van der Aalst, W.M.P., Bichler, M., Heinzl, A.: Responsible data science. Bus. Inf. Syst. Eng. 59(5), 311\u2013313 (2017)","journal-title":"Bus. Inf. Syst. Eng."},{"issue":"2","key":"9_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s44206-024-00105-2","volume":"3","author":"G Pisoni","year":"2024","unstructured":"Pisoni, G., Moloney, M.: Responsible AI-based business process management and improvement. Dig. Soc. 3(2), 23 (2024). https:\/\/doi.org\/10.1007\/s44206-024-00105-2","journal-title":"Dig. Soc."},{"issue":"11","key":"9_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/archneur.1983.04050100042016","volume":"40","author":"LC Scheinberg","year":"1983","unstructured":"Scheinberg, L.C., Goldsmith, L.S.: Ethical and legal aspects of clinical trials. Arch. Neurol. 40(11), 702 (1983)","journal-title":"Arch. Neurol."},{"issue":"4","key":"9_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/216847900604000402","volume":"40","author":"AE Shamoo","year":"2006","unstructured":"Shamoo, A.E., Resnik, D.B.: Ethical issues for clinical research managers. Drug Inf. J. 40(4), 371\u2013383 (2006)","journal-title":"Drug Inf. J."},{"issue":"7","key":"9_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jme.2004.008771","volume":"31","author":"AS Iltis","year":"2005","unstructured":"Iltis, A.S.: Stopping trials early for commercial reasons: the risk\u2013benefit relationship as a moral compass: Table 1. J. Med. Ethics 31(7), 410\u2013414 (2005). https:\/\/doi.org\/10.1136\/jme.2004.008771","journal-title":"J. Med. Ethics"},{"key":"9_CR21","doi-asserted-by":"crossref","unstructured":"Jyothula, C.J., Sithole, T.: Digital twins in healthcare, pp. 48\u201368 (2024)","DOI":"10.4018\/979-8-3693-5893-1.ch003"},{"issue":"10","key":"9_CR22","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.ifacol.2022.10.038","volume":"55","author":"P Zuhr","year":"2022","unstructured":"Zuhr, P., Rissmann, L., Mei\u00dfner, S.: Framework for planning and implementation of Digital Process Twins in the field of internal logistics. IFAC-PapersOnLine 55(10), 2221\u20132227 (2022)","journal-title":"IFAC-PapersOnLine"},{"key":"9_CR23","doi-asserted-by":"crossref","unstructured":"Pop, E., Iliu\u0163\u0103, M.-E., Moisescu, M. A.: Digital twin types and applications in healthcare (2024)","DOI":"10.3233\/SHTI241056"},{"key":"#cr-split#-9_CR24.1","unstructured":"Ashok, P., Pillai, S.: Transforming cold chain management: the role of digital twins in post-harvest logistics. In: 2024 2nd World Conference on Communication"},{"key":"#cr-split#-9_CR24.2","unstructured":"Computing (WCONF), pp. 1-6. IEEE (2024)"},{"issue":"8","key":"9_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","volume":"134","author":"DG Altman","year":"2001","unstructured":"Altman, D.G., et al.: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann. Intern. Med. 134(8), 663\u2013694 (2001)","journal-title":"Ann. Intern. Med."},{"issue":"sup1","key":"9_CR26","doi-asserted-by":"publisher","first-page":"1694744","DOI":"10.1080\/16549716.2019.1694744","volume":"13","author":"T Vian","year":"2020","unstructured":"Vian, T.: Anti-corruption, transparency and accountability in health: concepts, frameworks, and approaches. Glob. Health Action 13(sup1), 1694744 (2020)","journal-title":"Glob. Health Action"},{"issue":"1","key":"9_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2105\/AJPH.2011.300187","volume":"102","author":"JS Ross","year":"2012","unstructured":"Ross, J.S., Gross, C.P., Krumholz, H.M.: Promoting transparency in pharmaceutical industry-sponsored research. Am. J. Public Health 102(1), 72\u201380 (2012)","journal-title":"Am. J. Public Health"},{"issue":"12","key":"9_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017917","volume":"7","author":"JE Miller","year":"2017","unstructured":"Miller, J.E., Wilenzick, M., Ritcey, N., Ross, J.S., Mello, M.M.: Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open 7(12), e017917 (2017)","journal-title":"BMJ Open"},{"issue":"5","key":"9_CR29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMe1307268","volume":"369","author":"DA Zarin","year":"2013","unstructured":"Zarin, D.A.: Participant-level data and the new frontier in trial transparency. N. Engl. J. Med. 369(5), 468\u2013469 (2013)","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"9_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12916-016-0587-5","volume":"14","author":"SG Nicholls","year":"2016","unstructured":"Nicholls, S.G., Langan, S.M., Benchimol, E.I., Moher, D.: Reporting transparency: making the ethical mandate explicit. BMC Med. 14(1), 44 (2016)","journal-title":"BMC Med."},{"issue":"7286","key":"9_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/bmj.322.7286.569","volume":"322","author":"S Evans","year":"2001","unstructured":"Evans, S.: Societal responsibilities of clinical trial sponsors. BMJ 322(7286), 569\u2013570 (2001)","journal-title":"BMJ"},{"issue":"1","key":"9_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13063-017-1827-5","volume":"18","author":"A Matheson","year":"2017","unstructured":"Matheson, A.: Marketing trials, marketing tricks \u2014 how to spot them and how to stop them. Trials 18(1), 105 (2017)","journal-title":"Trials"},{"issue":"5","key":"9_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/1740774519865517","volume":"16","author":"M Shabani","year":"2019","unstructured":"Shabani, M., Obasa, M.: Transparency and objectivity in governance of clinical trials data sharing: Current practices and approaches. Clin. Trials 16(5), 547\u2013551 (2019)","journal-title":"Clin. Trials"},{"issue":"2","key":"9_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cct.2014.01.001","volume":"37","author":"I Logvinov","year":"2014","unstructured":"Logvinov, I.: Clinical trials transparency and the Trial and Experimental Studies Transparency (TEST) act. Contemp. Clin. Trials 37(2), 219\u2013224 (2014)","journal-title":"Contemp. Clin. Trials"},{"key":"9_CR35","doi-asserted-by":"crossref","unstructured":"DeVito, N.J., Morley, J., Goldacre, B.: Barriers and best practices to improving clinical trials transparency at UK public research institutions: a qualitative interview study. Health Policy (New York) 142, 104991 (2024)","DOI":"10.1016\/j.healthpol.2024.104991"},{"key":"9_CR36","doi-asserted-by":"crossref","unstructured":"Abdul Razack, H.I., Aranjani, J.M., Mathew, S.T.: Clinical trial transparency regulations: implications to various scholarly publishing stakeholders. Sci. Public Policy 49(6), 951\u2013961 (2022)","DOI":"10.1093\/scipol\/scac041"},{"issue":"4","key":"9_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0197-2456(99)00014-8","volume":"20","author":"VW Berger","year":"1999","unstructured":"Berger, V.W., Exner, D.V.: Detecting selection bias in randomized clinical trials. Control. Clin. Trials 20(4), 319\u2013327 (1999)","journal-title":"Control. Clin. Trials"},{"issue":"1","key":"9_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12910-018-0253-x","volume":"19","author":"CE Goldstein","year":"2018","unstructured":"Goldstein, C.E., et al.: Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation. BMC Med. Ethics 19(1), 14 (2018)","journal-title":"BMC Med. Ethics"},{"issue":"5","key":"9_CR39","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ana.1025","volume":"49","author":"FD Lublin","year":"2001","unstructured":"Lublin, F.D., Reingold, S.C.: Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. Ann. Neurol. 49(5), 677\u2013681 (2001)","journal-title":"Ann. Neurol."},{"issue":"1","key":"9_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0197-2456(80)80005-5","volume":"1","author":"K Lebacqz","year":"1980","unstructured":"Lebacqz, K.: Controlled clinical trials: some ethical issues. Control. Clin. Trials 1(1), 29\u201336 (1980)","journal-title":"Control. Clin. Trials"},{"issue":"5\u20136","key":"9_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00508-006-0577-2","volume":"118","author":"K Liddell","year":"2006","unstructured":"Liddell, K., et al.: Recommendations in relation to the EU Clinical Trials Directive and Medical Research Involving Incapacitated Adults. Wien. Klin. Wochenschr. 118(5\u20136), 183\u2013191 (2006)","journal-title":"Wien. Klin. Wochenschr."},{"issue":"1","key":"9_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jama.2024.0269","volume":"333","author":"NE Kass","year":"2025","unstructured":"Kass, N.E., Faden, R.R., Angus, D.C., Morain, S.R.: Making the ethical oversight of all clinical trials fit for purpose. JAMA 333(1), 75 (2025)","journal-title":"JAMA"},{"issue":"5","key":"9_CR43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1740774515598334","volume":"12","author":"RM Califf","year":"2015","unstructured":"Califf, R.M., Sugarman, J.: Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin. Trials 12(5), 436\u2013441 (2015)","journal-title":"Clin. Trials"},{"issue":"1","key":"9_CR44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s13063-023-07802-2","volume":"24","author":"S Crosby","year":"2023","unstructured":"Crosby, S., Malavisi, A., Huang, L., Jan, S., Holden, R., Neal, B.: Factors influencing the time to ethics and governance approvals for clinical trials: a retrospective cross-sectional survey. Trials 24(1), 779 (2023)","journal-title":"Trials"},{"key":"9_CR45","doi-asserted-by":"crossref","unstructured":"Ashcroft, C., Clark, E., Frith, H.: Implications of socio-cultural contexts for the ethics of clinical trials.. Health Technol. Assess (Rockv) 1(9) (1997)","DOI":"10.3310\/hta1090"},{"issue":"4","key":"9_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/jmp\/11.4.385","volume":"11","author":"JB Kadane","year":"1986","unstructured":"Kadane, J.B.: Progress toward a more ethical method for clinical trials. J. Med. Philos. 11(4), 385\u2013404 (1986)","journal-title":"J. Med. Philos."},{"issue":"3","key":"9_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10637-018-0577-x","volume":"36","author":"A Ozaki","year":"2018","unstructured":"Ozaki, A., Takita, M., Tanimoto, T.: A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine. Invest. New Drugs 36(3), 517\u2013522 (2018)","journal-title":"Invest. New Drugs"},{"issue":"5","key":"9_CR48","doi-asserted-by":"publisher","DOI":"10.2196\/33591","volume":"24","author":"N Gudi","year":"2022","unstructured":"Gudi, N., et al.: Regulatory frameworks for clinical trial data sharing: scoping review. J. Med. Internet Res. 24(5), e33591 (2022)","journal-title":"J. Med. Internet Res."},{"issue":"6","key":"9_CR49","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1359\/jbmr.2003.18.6.1142","volume":"18","author":"M Rosenblatt","year":"2003","unstructured":"Rosenblatt, M.: Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective. J. Bone Miner. Res. 18(6), 1142\u20131145 (2003)","journal-title":"J. Bone Miner. Res."}],"container-title":["Lecture Notes in Business Information Processing","Business Process Management: Responsible BPM Forum, Process Technology Forum, Educators Forum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-02936-2_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:19:31Z","timestamp":1757481571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-02936-2_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"ISBN":["9783032029355","9783032029362"],"references-count":50,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-02936-2_9","relation":{},"ISSN":["1865-1348","1865-1356"],"issn-type":[{"type":"print","value":"1865-1348"},{"type":"electronic","value":"1865-1356"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"30 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"BPM","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Conference on Business Process Management","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Seville","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Spain","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2025","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"31 August 2025","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"5 September 2025","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"23","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"bpm2025","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"http:\/\/www.bpm2025seville.org\/","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}}]}}